**Title: Groundbreaking Advances in Women’s Health: A Conversation with Aspira Women’s Health CEO and CSO**
Welcome to New to the Street, your ultimate source for the latest updates in the world of crypto, blockchain, and business news. In this episode, we have a special conversation with Nicole Sandford, President, CEO, and Board Member, and Dr. Ryan Phan, Ph.D., Chief Scientific Officer and Chief Operating Officer of Aspira Women’s Health. Tune in as they delve into the innovative developments in women’s reproductive health and gynecologic disorders.
Aspira Women’s Health (NASDAQ: AWH) is revolutionizing the field of women’s health with their data-driven approach and cutting-edge diagnostic tools. With a focus on risk assessment, AWH develops and markets advanced blood-based diagnostic kits that detect gynecologic diseases. One of their notable products is the ovarian cancer test kit, an advanced diagnostic tool that aids doctors and patients in making informed medical decisions and evaluating treatment options.
Ovarian cancer is notoriously difficult to detect, often resulting in late-stage diagnoses with lower survival rates. With their pioneering OvaWatchSM kit, launched in 2022, AWH aims to provide monitoring and management for ovarian masses. The ongoing clinical trials for this kit hold great promise for monitoring patients diagnosed with an adnexal mass, allowing for more tailored treatment plans.
Dr. Phan shares insights into his educational background and expertise in the healthcare sector, which motivated him to join AWH. He discusses the development of the EndoCheck™ test kit, designed to address the challenges of diagnosing endometriosis. This debilitating disease affects millions of women worldwide and often goes undetected for long periods, leading to significant pain and impact on daily life. The EndoCheck™ test kit promises to be a non-invasive diagnostic tool that aids in forecasting and managing endometriosis, providing a much-needed alternative to costly and invasive procedures.
Nicole and Ryan are dedicated to empowering women and healthcare providers with innovative solutions for ovarian cancer, endometriosis, and other gynecologic disorders. To learn more about Aspira Women’s Health and their groundbreaking advancements, visit their website [here](https://aspirawh.com/).
Be sure to catch this insightful interview on Newsmax (episode 474) airing on June 3, 2023, at 3:30 PM ET, and on the FOX Business Network (episode 475) airing on June 5, 2023, at 10:30 PM PT.
Don’t miss out on the latest updates and informative videos from New to the Street! Subscribe to our YouTube channel [here](https://www.youtube.com/c/newtothestreettv) and stay connected with us on our social media platforms:
About New to the Street:
New to the Street is the go-to platform for comprehensive coverage of crypto, blockchain, and business news. Stay informed and subscribe to our [mailing list](https://mailchi.mp/ccd21b3e3fab/join-our-mailing-list) for regular updates.
– [Aspira Women’s Health](https://aspirawh.com/)
– [About New to the Street](https://newtothestreet.com/)
– [Subscribe to our Mailing List](https://mailchi.mp/ccd21b3e3fab/join-our-mailing-list)
crypto, cryptocurrency, blockquake, blockchain, blockchain news, digital currency, newtothestreet, janeking, exploringtheblock, fox business news, fox business, financial news, business news, ai, newsmaxtv
**Transcript (selected excerpts):**
*”Our company is focused on developing Advanced Diagnostic tools for gynecologic diseases using technology and we’ve been focused on gynecologic disease since our Inception… We started focused on ovarian cancer which we talked about last time… and we’re building out our pipeline to focus on other gynecologic diseases based on the success of that commercial product…”* ([source](https://www.youtube.com/watch?v=VIDEO_ID&t=1m19s))
*”More than 60 percent of women are diagnosed in stage Three or stage four [of ovarian cancer] and the chances of surviving ovarian cancer at that late stage are 30 or less depending on the type and the uh the stage that it’s identified… we have the OvaWatchSM kit… launched in 2022, is an ovarian mass monitoring and management test…”* ([source](https://www.youtube.com/watch?v=VIDEO_ID&t=2m35s))
*”Endometriosis is a devastating disease… It takes a very long time to diagnose… women suffer with debilitating Pain that often interferes with their ability to work go to school live their lives… there’s not a currently available diagnostic tool… so finding out what you’re dealing with for these women is critical… The EndoCheck™ test kit can become a more beneficial tool for an endometriosis diagnosis…”* ([source](https://www.youtube.com/watch?v=VIDEO_ID&t=5m47s))
Click the Subscribe button for the latest in crypto, blockchain and business news from NEW TO THE STREET!
#crypto #cryptocurrency #blockquake #blockchain #blockchainnews #digitalcurrency #newtothestreet #janeking #exploringtheblock #foxbusinessnews #foxbusiness #financialnews #businessnews #ai #newsmaxtv
Nicole Sandford, President, CEO, and Board Member, and Dr. Ryan Phan, Ph.D., Chief Scientific Officer ,and Chief Operating Officer of Aspira Women’s Health (NASDAQ: AWH) ($AWH) are at the Nasdaq MarketSite studio talking with New to The Street’s TV Host Jane King. The Company focuses on women’s reproductive health and other gynecologic disorders. AWH develops and markets advanced blood-based diagnostic kits that detect gynecology diseases that focus on risk assessments. AWH’s ovarian cancer test kit is an advanced diagnostic tool that helps doctors and patients make sensible medical decisions and evaluate treatment options. Nicole explains to viewers that ovarian cancer is hard to determine, and once diagnosed, unfortunately, the cancer is sometimes at stages 3 or 4, with about a 30% survival rate. The OvaWatchSM kit, launched in 2022, is an ovarian mass monitoring and management test. The Company is advancing the OvaWatch test, awaiting clinical results to be published; upon a successful outcome, this test can assist further in monitoring patients diagnosed with an adnexal mass. Dr. Phan talks about his educational background and professional experiences in the healthcare sector. He joined AWH in 2022 because of the quality of the team members, the current product kit offerings, and future pipeline products. He talks about endometriosis and the ongoing development of the Company’s EndoCheck™ test kit. Endometriosis affects millions of women globally, and a non-invasive diagnostic tool can assist patients in forecasting and managing the disease. Drugs are available to help control endometriosis, but they are expensive, and a patient needs to prove a positive endometriosis diagnosis to get the drugs. Painful medical procedures are the only way to confirm a diagnosis of endometriosis. Once available, the EndoCheck™ test kit can become a more beneficial tool for an endometriosis diagnosis. Nicole and Ryan dedicate themselves to helping women with ovarian cancer and other gynecologic disorders. The on-screen QR code is available during the show to download more info or visit Aspira Women’s Health – https://aspirawh.com/. The interview will air on Newsmax, episode 474, on June 3, 2023, at 3:30 PM ET, and the FOX Business Network, episode 475, on June 5, 2023, at 10:30 PM PT.
To make sure you never miss a video from New to the Street, click here to subscribe: https://www.youtube.com/c/newtothestreettv
Follow New to the Street on Twitter: https://twitter.com/NewToTheStreet
Follow New to the Street on Facebook: https://www.facebook.com/newtothestreet/
Follow New to the Street on Instagram: https://www.instagram.com/newtothestreettv/
Follow New to the Street on Rumble: https://rumble.com/user/newtothestreet
About New to the Street: https://newtothestreet.com/
Subscribe to our Mailing List: https://mailchi.mp/ccd21b3e3fab/join-our-mailing-list